Welcome to our dedicated page for Alpha Tau Medical SEC filings (Ticker: DRTSW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer. Alpha Tau files reports such as Form 20-F annual reports and Form 6-K current reports under the Securities Exchange Act of 1934, which together outline its clinical-stage oncology activities, financial position, and material company announcements related to the Alpha DaRT® platform.
Form 6-K filings referenced in the available data include interim consolidated financial statements, operating and financial reviews, and press releases covering topics such as clinical trial updates, investor conference participation, and corporate developments. For example, a 6-K dated August 11, 2025 attaches interim consolidated financial statements as of June 30, 2025 and an operating and financial review, and incorporates these documents by reference into Alpha Tau’s registration statements on Form F-3 and Form S-8. Other 6-Ks furnish press releases about clinical milestones, including treatment of the first patient in a U.S. multi-center pancreatic cancer trial.
Through these filings, investors can review Alpha Tau’s reported research and development expenses, marketing and general and administrative costs, net loss figures, and balance sheet data, as well as narrative discussion of factors that may affect its business. The company’s forward-looking statements sections list risks such as the need for regulatory approvals for Alpha DaRT, limited operating history, ongoing losses, funding requirements, clinical trial uncertainties, and compliance with Nasdaq listing standards and other regulations.
On Stock Titan, SEC filings for Alpha Tau can be viewed alongside AI-powered tools that summarize lengthy documents and highlight key sections, helping readers interpret interim financial statements, risk factor discussions, and exhibit lists. Users interested in DRTS and DRTSW can use this page to track the company’s furnished 6-K reports, annual 20-F filings, and related disclosures that document Alpha Tau’s clinical-stage progress and capital markets activity.
Alpha Tau Medical Ltd. filed a Form 6-K furnishing its interim consolidated financial statements as of June 30, 2025 and an operating and financial review for the six months ended June 30, 2025. These documents, plus an August 11, 2025 press release, are incorporated by reference into multiple existing Form F-3 and Form S-8 registration statements.